Clinical Scorecard: Strategies for Policy and Reimbursement to Enhance Patient Access to Prescription Digital Therapeutics
At a Glance
Category
Detail
Condition
Various chronic and acute conditions including substance use disorders, mental health, women’s health, stroke recovery, cancer
Key Mechanisms
FDA-cleared software delivering evidence-based treatments via Software as a Medical Device (SaMD), including behavioral therapy, gamified CBT, Virtual Reality, and emerging AI mechanisms
Target Population
Patients requiring digital therapeutic interventions, including underserved populations and those with limited access to in-person care
Care Setting
Outpatient or Part B settings, remote and on-demand care environments
Key Highlights
Prescription Digital Therapeutics (PDTs) are FDA-cleared software treatments with demonstrated clinical and economic benefits but face outdated U.S. reimbursement frameworks limiting access.
The Access to Prescription Digital Therapeutics Act proposes a dedicated Medicare benefit category to streamline reimbursement and align PDTs with evidence-based interventions.
Global models like Germany’s DiGA program illustrate scalable national reimbursement frameworks that improve access while emphasizing real-world evidence and safety.
Guideline-Based Recommendations
Diagnosis
Utilize FDA-cleared PDTs as adjunct or alternative treatments for appropriate clinical conditions based on evidence and provider prescription.
Management
Incorporate PDTs into treatment plans to complement or replace traditional therapies where clinically indicated.
Support integration of PDTs with drug therapies, such as behavioral therapy alongside medication-assisted treatment.
Monitoring & Follow-up
Encourage robust post-market data collection to assess real-world clinical outcomes, safety, and economic value of PDTs.
Risks
Recognize that early implementations may be limited to low-risk devices; monitor for sustained efficacy and safety to avoid withdrawal of ineffective products.
Patient & Prescribing Data
Patients with conditions amenable to digital therapeutic interventions, including those in underserved or remote areas
PDTs offer on-demand, accessible care that can reduce barriers to treatment and potentially lower healthcare costs by preventing more expensive downstream care.
Clinical Best Practices
Advocate for updated reimbursement policies that reflect the clinical rigor and innovation of PDTs.
Prescribe FDA-cleared PDTs when evidence supports their use and patient access is feasible.
Monitor patient engagement and outcomes to ensure effectiveness and safety of PDT interventions.
Support policy efforts to establish clear benefit categories and reimbursement pathways for PDTs, including those incorporating AI mechanisms.
